Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038510 | 1.00 | HPGD (0.56) | HPGDGAACA12CA1CA2 | |
| SCHEMBL9658993 | 0.93 | — | — | |
| SCHEMBL2314238 | 0.93 | — | — | |
| SCHEMBL16051303 | 0.84 | — | — | |
| SCHEMBL20054235 | 0.83 | HPGD (0.53) | HPGDGAACA12CA1CA2 | |
| SCHEMBL4028484 | 0.82 | HPGD (0.60) | HPGDGAACA12CA1CA2 | |
| SCHEMBL23581941 | 0.80 | HPGD (0.50) | HPGDGAACA12CA1CA2 | |
| SCHEMBL14439211 | 0.80 | HPGD (0.58) | HPGDGAACA12CA1CA2 | |
| SCHEMBL7888486 | 0.80 | HPGD (0.58) | HPGDGAACA12CA1CA2 | |
| SCHEMBL420108 | 0.80 | HPGD (0.58) | HPGDGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0686698-B1 | Biotechnological process for the production of cyclic S-alpha-aminocarboxylic acids and R-alpha-aminocarboxylic acid amides | LONZA AG (CH) | 2001-03-14 | — | — | EP | claimed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2014195400-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | TLR7, TLR9, TLR1 | HPGD 1528/4885GAA 1929/4885CA12 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.